Fulcrum Therapeutics Inc. (FULC) Tops Q4 EPS by 12c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q4 EPS of ($0.71), $0.12 better than the analyst estimate of ($0.83).

“We made important progress at a rapid pace in 2019 as we transitioned from a private, discovery company into a public, clinical-stage company,” said Robert J. Gould, president and chief executive officer. “In our losmapimod program for patients with facioscapulohumeral muscular dystrophy (FSHD), we completed enrollment in our Phase 2 clinical trials, including ReDUX4, the randomized, double-blind placebo-controlled multicenter international Phase 2b clinical trial, and we continue to expect to announce topline data on the primary endpoint in the third quarter of 2020. We also plan to submit an IND for FTX-6058 for the treatment of sickle cell disease in the second half of this year. We look forward to building on this progress as we execute on our goal of advancing therapies focused on improving the lives of patients with genetically defined diseases.”

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• Ladder Capital (LADR) Tops Q1 EPS by 4c
• HarborOne Bancorp, Inc. (HONE) Tops Q1 EPS by 6c